XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenue:        
Total revenue $ 50,641 $ 44,319 $ 106,544 $ 80,480
Operating costs and expenses:        
Cost of goods sold $ 5,178 $ 5,708 $ 30,931 $ 9,199
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 34,106 $ 95,478 $ 72,498 $ 169,964
Selling, general and administrative 22,276 31,181 45,097 65,455
Total operating costs and expenses 61,560 132,367 148,526 244,618
Loss from operations (10,919) (88,048) (41,982) (164,138)
Interest and other, net        
Interest expense (4,783) (3,069) (9,779) (5,441)
Interest income and other income (expenses), net (1,281) 2,652 1,289 3,687
Total interest and other, net (6,064) (417) (8,490) (1,754)
Loss before income taxes (16,983) (88,465) (50,472) (165,892)
Benefit from income taxes (262) (235) (229) (161)
Investment income in unconsolidated variable interest entity 1,177 550 1,766 1,346
Net loss $ (15,544) $ (87,680) $ (48,477) $ (164,385)
Net loss per share - basic $ (0.16) $ (0.9) $ (0.49) $ (1.71)
Net loss per share - diluted $ (0.16) $ (0.9) $ (0.49) $ (1.71)
Weighted average number of common shares used to calculate net loss per share:        
Basic 99,835 97,729 99,408 96,218
Diluted 99,835 97,729 99,408 96,218
License Revenue [Member]        
Revenue:        
Total revenue $ 0 $ 1,000 $ 0 $ 7,000
Development and Other Revenue [Member]        
Revenue:        
Total revenue 269 5,158 1,147 9,050
Product Revenue, Net [Member]        
Revenue:        
Total revenue 49,643 23,889 80,181 48,049
Drug Product Revenue, Net [Member]        
Revenue:        
Total revenue $ 729 $ 14,272 $ 25,216 $ 16,381